Optimal timing of aspirin discontinuation after acute coronary syndrome treated with percutaneous coronary intervention: a systematic review and meta-analysis

Heart 2026

View at publisher
Authors: Kamil Bujak, Claudio Laudani, Riccardo Rinaldi, Paweł Łajczak, Mariusz Gąsior, Natalia Pawlas, L Ortega-Paz, Manel Sabaté, Salvatore Brugaletta
DOI: 10.1136/heartjnl-2026-328334
Cited by: 3
References: 38

Abstract

Background In patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI), abbreviated dual antiplatelet therapy (DAPT) reduces bleeding as compared with standard DAPT. Still, the optimal timing of aspirin discontinuation remains uncertain. We aimed to compare the net benefits of aspirin discontinuation timing in short DAPT followed by P2Y 12 inhibitor monotherapy versus standard DAPT. Methods We performed pairwise and network meta-analyses (NMAs) to directly and indirectly compare short DAPT (aspirin-free,

Fields of Study & Subjects

Antiplatelet Therapy and Cardiovascular Diseases Coronary Interventions and Diagnostics Atrial Fibrillation Management and Outcomes

Publication details

Journal / source
Heart
Publisher
BMJ
Pages
heartjnl–2026
Publication date
26 June 2026
Language
EN